Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Bacterial Keratitis Follow-up

  • Author: Fernando H Murillo-Lopez, MD; Chief Editor: Hampton Roy, Sr, MD  more...
 
Updated: Aug 28, 2014
 

Further Outpatient Care

See the list below:

  • Patients need to be monitored closely to make certain the infection is responding to treatment as the medications are tapered.
Next

Further Inpatient Care

See the list below:

  • The frequency of antibiotic administration should be tapered off gradually according to the clinical improvement using some of the following parameters:
    • Blunting of the perimeter of the stromal infiltrate
    • Decreased density of the stromal infiltrate
    • Decreased stromal edema and endothelial inflammatory plaque
    • Decreased anterior chamber inflammation and reepithelialization of the corneal epithelial defect
  • Improvement of patient's symptoms
Previous
Next

Inpatient & Outpatient Medications

See the list below:

  • The antibiotic medications are decreased slowly, depending on the culture and sensitivity results and the clinical response. If topical steroids are used, the antibiotic should not be discontinued.
Previous
Next

Deterrence/Prevention

See the list below:

  • Topical antibiotics are given routinely after traumatic injury to the cornea (including surgery).
  • Preventing contamination of topical medications and the use of sterile contact lens solutions are critical steps in preventing contact lens-related infections.
Previous
Next

Complications

See the list below:

  • The most feared complication of this condition is thinning of the cornea, secondary descemetocele, and eventual perforation of the cornea that may result in endophthalmitis and loss of the eye.
Previous
Next

Prognosis

See the list below:

  • The visual prognosis depends on several factors, as outlined below, and may result in a mild-to-severe decrease in best-corrected visual acuity.
    • Virulence of the organism responsible for the keratitis
    • Extent and location of the corneal ulcer
    • Resulting vascularization and/or collagen deposition
Previous
Next

Patient Education

See the list below:

  • Patients who are contact lens wearers (in particular extended-wear contact lenses) should be instructed not to force the use of contact lenses when they have hyperemia, irritation, or foreign body sensation, and to use sterile contact lens solutions to avoid contamination.
  • For excellent patient education resources, visit eMedicineHealth's Eye and Vision Center. Also, see eMedicineHealth's patient education article Corneal Ulcer.
Previous
 
Contributor Information and Disclosures
Author

Fernando H Murillo-Lopez, MD Senior Surgeon, Unidad Privada de Oftalmologia CEMES

Fernando H Murillo-Lopez, MD is a member of the following medical societies: American Academy of Ophthalmology

Disclosure: Nothing to disclose.

Specialty Editor Board

Simon K Law, MD, PharmD Clinical Professor of Health Sciences, Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, American Glaucoma Society

Disclosure: Nothing to disclose.

Christopher J Rapuano, MD Professor, Department of Ophthalmology, Jefferson Medical College of Thomas Jefferson University; Director of the Cornea Service, Co-Director of Refractive Surgery Department, Wills Eye Hospital

Christopher J Rapuano, MD is a member of the following medical societies: American Academy of Ophthalmology, American Ophthalmological Society, American Society of Cataract and Refractive Surgery, Contact Lens Association of Ophthalmologists, International Society of Refractive Surgery, Cornea Society, Eye Bank Association of America

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cornea Society, Allergan, Bausch & Lomb, Bio-Tissue, Shire, TearScience, TearLab<br/>Serve(d) as a speaker or a member of a speakers bureau for: Allergan, Bausch & Lomb, Bio-Tissue, TearScience.

Chief Editor

Hampton Roy, Sr, MD Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy, Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Additional Contributors

Jack L Wilson, PhD Distinguished Professor, Department of Anatomy and Neurobiology, University of Tennessee Health Science Center College of Medicine

Jack L Wilson, PhD is a member of the following medical societies: American Association of Anatomists, American Heart Association, American Association of Clinical Anatomists

Disclosure: Nothing to disclose.

References
  1. Hall BJ, Jones L. Contact Lens Cases: The Missing Link in Contact Lens Safety?. Eye Contact Lens. 2010 Jan 19. [Medline].

  2. Khan YA, Kashiwabuchi RT, Martins SA, Castro-Combs JM, Kalyani S, Stanley P. Riboflavin and ultraviolet light a therapy as an adjuvant treatment for medically refractive acanthamoeba keratitis report of 3 cases. Ophthalmology. 2011 Feb. 118(2):324-31. [Medline].

  3. Haas W, Pillar CM, Torres M, Morris TW, Sahm DF. Monitoring Antibiotic Resistance in Ocular Microorganisms: Results From the Antibiotic Resistance Monitoring in Ocular MicRorganisms (ARMOR) 2009 Surveillance Study. Am J Ophthalmol. 2011 Oct. 152(4):567-574.e3. [Medline].

  4. Lalitha P, Srinivasan M, Manikandan P, Bharathi MJ, Rajaraman R, Ravindran M, et al. Relationship of In Vitro Susceptibility to Moxifloxacin and In Vivo Clinical Outcome in Bacterial Keratitis. Clin Infect Dis. 2012 Mar 23. [Medline].

  5. Bower KS, Kowalski RP, Gordon YJ. Fluoroquinolones in the treatment of bacterial keratitis. Am J Ophthalmol. 1996 Jun. 121(6):712-5. [Medline].

  6. Caballero AR, Marquart ME, O'Callaghan RJ, Thibodeaux BA, Johnston KH, Dajcs JJ. Effectiveness of fluoroquinolones against Mycobacterium abscessus in vivo. Curr Eye Res. 2006 Jan. 31(1):23-9. [Medline].

  7. Genvert GI, Cohen EJ, Donnenfeld ED. Erythema multiforme after use of topical sulfacetamide. Am J Ophthalmol. 1985 Apr 15. 99(4):465-8. [Medline].

  8. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology. 1999 Jul. 106(7):1313-8. [Medline].

  9. Hirst LW, Harrison GK, Merz WG. Nocardia asteroides keratitis. Br J Ophthalmol. 1979 Jun. 63(6):449-54. [Medline].

  10. Hirst LW, Smiddy WE, Stark WJ. Corneal perforations. Changing methods of treatment, 1960--1980. Ophthalmology. 1982 Jun. 89(6):630-5. [Medline].

  11. Hyndiuk RA, Eiferman RA, Caldwell DR. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. Ophthalmology. 1996 Nov. 103(11):1854-62; discussion 1862-3. [Medline].

  12. Knapp A, Stern GA, Hood CI. Mycobacterium avium-intracellulare corneal ulcer. Cornea. 1987. 6(3):175-80. [Medline].

  13. Leibowitz HM. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis. Am J Ophthalmol. 1991 Oct. 112(4 Suppl):34S-47S. [Medline].

  14. Moore MB, Newton C, Kaufman HE. Chronic keratitis caused by Mycobacterium gordonae. Am J Ophthalmol. 1986 Oct 15. 102(4):516-21. [Medline].

  15. Newman PE, Goodman RA, Waring GO 3d. A cluster of cases of Mycobacterium chelonei keratitis associated with outpatient office procedures. Am J Ophthalmol. 1984 Mar. 97(3):344-8. [Medline].

  16. Parmar P, Salman A, Kalavathy CM. Comparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitis. Am J Ophthalmol. 2006 Feb. 141(2):282-286. [Medline].

  17. Pate JC, Jones DB, Wilhelmus KR. Prevalence and spectrum of bacterial co-infection during fungal keratitis. Br J Ophthalmol. 2006 Mar. 90(3):289-92. [Medline].

  18. Poggio EC, Glynn RJ, Schein OD. The incidence of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses. N Engl J Med. 1989 Sep 21. 321(12):779-83. [Medline].

  19. Schein OD, Glynn RJ, Poggio EC. The relative risk of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses. A case-control study. Microbial Keratitis Study Group. N Engl J Med. 1989 Sep 21. 321(12):773-8. [Medline].

  20. Schlech BA, Alfonso E. Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX). Surv Ophthalmol. 2005 Nov. 50 Suppl 1:S7-15. [Medline].

  21. Stern GA, Buttross M. Use of corticosteroids in combination with antimicrobial drugs in the treatment of infectious corneal disease. Ophthalmology. 1991 Jun. 98(6):847-53. [Medline].

  22. Stern GA, Schemmer GB, Farber RD. Effect of topical antibiotic solutions on corneal epithelial wound healing. Arch Ophthalmol. 1983 Apr. 101(4):644-7. [Medline].

  23. Varma R, eds. Cornea/external diseases. Essentials of Eye Care: The Johns Hopkins Wilmer Handbook. Lippincott Williams & Wilkins. 1997:152-203.

Previous
Next
 
Human eye anatomy.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.